American Medical Association
Physician association promoting art/science of medicine and betterment of public health
Based in IL
🤖
AI Overview
With $1.7M in lobbying spend across 28 quarterly filings, American Medical Association is a significant lobbying presence.
$1.7M
Total Lobbying Spend
28
Quarterly Filings
1
Lobbying Firms Used
5
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $180K |
| 2020 | $240K |
| 2021 | $180K |
| 2022 | $180K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $240K |
Lobbying Firms
AVENUE SOLUTIONS
What They Lobby For
- MACRA implementation and issues related to misvalued codes; Insurance market stabilization policies; Cost-sharing reduction subsidies (Alexander-Murray proposal); Issues related to opioids policies; Issues related to healthcare discussions in budget deal and healthcare extender policies; H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018; H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
- Issues related to opioids policies; H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act (SUPPORT for Patients and Communities Act); S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018); S. 2680, Opioid Crisis Response Act of 2018; Monitor drug pricing initiatives
- MACRA implementation and issues related to misvalued codes
- Issues related to opioids policies; H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act (SUPPORT for Patients and Communities Act); S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018); S. 2680, Opioid Crisis Response Act of 2018; Monitor drug pricing initiatives; Confidentiality related to substance use disorder patient medical records; Surprise billing issues; S. 1850, Protecting Jessica Grubb's Legacy Act - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records; Issues related to 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records
- MACRA implementation and issues related to evaluation and management (E&M) codes
- Issues related to opioids policies; H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act (SUPPORT for Patients and Communities Act); S. 3120, Helping to End Addiction and Lessen Substance Use Disorders Act of 2018 (HEAL Act of 2018); S. 2680, Opioid Crisis Response Act of 2018; Monitor drug pricing initiatives; Confidentiality related to substance use disorder patient medical records; Surprise billing issues, Senate price transparency working group draft legislation; S. 1850, Protecting Jessica Grubb's Legacy Act - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records; Issues related to 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records
- MACRA implementation and issues related to evaluation and management (E&M) codes; GAO study on geographic practice cost indicators (GPCI)
- Issues related to opioids policies; Issues related to the Trump Administration's support for Texas lawsuit that would rule ACA unconstitutional; Confidentiality related to substance use disorder patient medical records; Monitor issues related to healthcare cost, surprise billing issues and transparency; Issues related to 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records; Issues related to strengthening and protecting the Afortable Care Act including, H.R. 1385, SAVE Act; H.R. 1386, ENROLL Act of 2019; H.R. 987, MORE Health Education Act; H.R. 1010, To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; H.R. 986, Protecting Americans with Preexisting Conditions Act of 2019; H.R. 1425, State Health Care Premium Reduction Act; Issues related to gun control
- Issues related to Title X, funding for family planning services
- Issues related to opioids policies; Issues related to the Trump Administration's support for Texas lawsuit that would rule ACA unconstitutional; Confidentiality related to substance use disorder patient medical records; Monitor issues related to healthcare cost, surprise billing issues and transparency; Issues related to 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records; S. 1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 3630, No Surprises Act; H.R. 3502, Protecting People From Surprise Medical Bills Act; H.R. 861, End Surprise Billing Act of 2019
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.